INTELLIGENT BIO SOLUTIONS INC.

INBS Nasdaq CIK: 0001725430

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 135 W 41ST ST,, NEW YORK, NY, 10036
Mailing Address 135 W 41ST ST,, NEW YORK, NY, 10036
Phone 646-790-5756
Fiscal Year End 0630
EIN 821512711

Financial Overview

FY2025

$13.78M
Total Assets
$8.33M
Stockholders' Equity
$6.30M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 12, 2026 View on SEC
10-Q Quarterly financial report February 12, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
S-3 Shelf registration for future offerings January 9, 2026 View on SEC
8-K Current report of material events January 8, 2026 View on SEC
8-K Current report of material events January 2, 2026 View on SEC
8-K Current report of material events December 31, 2025 View on SEC
8-K Current report of material events December 16, 2025 View on SEC
8-K Current report of material events December 12, 2025 View on SEC

Material Events

8-K Financial Distress December 16, 2025
High Impact
  • INTELLIGENT BIO SOLUTIONS INC. received a warning from Nasdaq because its stock price fell below the $1.00 minimum for 30 consecutive business days.
  • To avoid delisting, the company immediately performed a reverse stock split, reducing the number of shares and proportionally increasing the price per share.
View Analysis
8-K Other December 12, 2025
High Impact
  • INTELLIGENT BIO SOLUTIONS INC. successfully completed the final testing phase for its new "Bio-Regen" cell therapy, making it ready for regulatory approval.
  • The company announced a one-for-ten (1-for-10) reverse stock split, effective December 15, 2025, to meet Nasdaq listing requirements.
View Analysis

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.